GlaxoSmithKline LLC v. Natco Pharma Ltd. - 1:26-cv-00168

GlaxoSmithKline LLC v. Natco Pharma Ltd. (Case No. 1:26-cv-00168), filed on Feb 13, 2026 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:26-cv-00168
Filing Date
Feb 13, 2026
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Natco Pharma Ltd. -
Merck Sharp & Dohme LLC -
GlaxoSmithKline LLC -
TESARO, Inc. -

Patents Involved

This case involves 2 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US11091459B2
-US11673877B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Feb 17, 2026COMPLAINT for Patent Infringement filed against Natco Pharma Ltd., Natco Pharma USA LLC ( Filing fee $ 405, receipt number ADEDC-4900762.) - filed by GlaxoSmithKline LLC, Merck Sharp & Dohme LLC, TESARO, Inc. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(mrr) (Entered: 02/17/2026)PACER Document
Feb 17, 2026Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) (Entered: 02/17/2026)PACER Document
Feb 17, 2026Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/9/2026. Date of Expiration of Patent: 11,091,459, Expiration date: 3/27/2038 & 11,673,877 Date of Expiration: 3/27/2038.Thirty Month Stay Deadline: 1/9/2028. (mrr) (Entered: 02/17/2026)PACER Document
Feb 17, 2026Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent GSK plc for GlaxoSmithKline LLC; Corporate Parent GlaxoSmithKline LLC, Other Affiliate GSK plc for TESARO, Inc. filed by GlaxoSmithKline LLC, TESARO, Inc. (mrr) (Entered: 02/17/2026)PACER Document
Feb 17, 2026Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme LLC filed by Merck Sharp & Dohme LLC. (mrr) (Entered: 02/17/2026)PACER Document
Feb 17, 2026Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,091,459; 11,673,877. (mrr) (Entered: 02/17/2026)PACER Document
Feb 17, 2026Summons Issued as to Natco Pharma Ltd. on 2/17/2026; Natco Pharma USA LLC on 2/17/2026. (Attachments: # 1 Summons Issued)(mrr) (Entered: 02/17/2026)PACER Document